Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) insider James Patrick Tursi acquired 4,750 shares of the company’s stock in a transaction dated Wednesday, March 15th. The stock was bought at an average cost of $2.11 per share, for a total transaction of $10,022.50. Following the completion of the transaction, the insider now directly owns 184,118 shares of the company’s stock, valued at $388,488.98. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) traded up 4.89% during trading on Monday, hitting $2.36. 4,483,632 shares of the company traded hands. The stock has a 50 day moving average price of $3.88 and a 200 day moving average price of $4.58. Aralez Pharmaceuticals Inc has a 12-month low of $2.05 and a 12-month high of $6.80. The company’s market capitalization is $154.58 million.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings data on Monday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.11. The firm had revenue of $20 million for the quarter, compared to analysts’ expectations of $21.86 million. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. Aralez Pharmaceuticals’s revenue was up 233.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.40) earnings per share. On average, equities analysts anticipate that Aralez Pharmaceuticals Inc will post ($1.07) earnings per share for the current year.
Your IP Address:
Separately, Chardan Capital decreased their price target on shares of Aralez Pharmaceuticals from $10.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, March 15th.
A number of institutional investors have recently bought and sold shares of the company. FNY Managed Accounts LLC increased its position in Aralez Pharmaceuticals by 13.5% in the third quarter. FNY Managed Accounts LLC now owns 59,000 shares of the company’s stock worth $286,000 after buying an additional 7,000 shares in the last quarter. Nwam LLC purchased a new position in Aralez Pharmaceuticals during the third quarter worth about $228,000. Wells Fargo & Company MN increased its position in Aralez Pharmaceuticals by 9.4% in the third quarter. Wells Fargo & Company MN now owns 260,769 shares of the company’s stock worth $1,265,000 after buying an additional 22,441 shares in the last quarter. Isthmus Partners LLC increased its position in Aralez Pharmaceuticals by 25.6% in the third quarter. Isthmus Partners LLC now owns 137,549 shares of the company’s stock worth $681,000 after buying an additional 28,054 shares in the last quarter. Finally, Advisor Group Inc. increased its position in Aralez Pharmaceuticals by 218.2% in the third quarter. Advisor Group Inc. now owns 115,184 shares of the company’s stock worth $559,000 after buying an additional 78,984 shares in the last quarter. 44.01% of the stock is currently owned by hedge funds and other institutional investors.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc and related companies with our FREE daily email newsletter.